A hospital in Spain, Álvaro Cunqueiro, has been internationally recognized as an important center for research on type 1 diabetes. This means that they can now participate in very relevant clinical trials worldwide.
One of these trials is called Beta-preserve, which includes eight children treated at this hospital. What they are investigating is a drug called Tzield (teplizumab), which has already been approved in Europe and which can delay the clinical onset of type 1 diabetes. This is something very new because until now we only had the option of controlling the disease with insulin, once the cells that produce insulin in the pancreas were already damaged.
One fact that caught my attention is that type 1 diabetes is a silent disease, and when the first symptoms appear, the organ is already very affected. Therefore, detecting people at risk earlier is essential. In this hospital they are already doing screening to identify patients in early stages, so that they can be candidates for treatments that stop the disease before it progresses.
Furthermore, another positive point is that the pediatric diabetes unit at this hospital works with advanced technology: all children have sensors to monitor sugar continuously without punctures, and most use smart insulin pumps that automatically adjust doses, making daily management much easier.
I think this advance is hopeful for all of us and for our children if they have type 1 diabetes. Do you think this type of research will change how we live with diabetes in the coming years? Would you like these new diagnosis and treatment options to be offered in more places?
Greetings,
Fountain: LINK